|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-9-18
|
|
pubmed:abstractText |
This study aimed to evaluate the effectiveness of omalizumab among adolescents with moderate-severe allergic asthma inadequately controlled with inhaled corticosteroids.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1938-2707
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
859-65
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19564449-Administration, Inhalation,
pubmed-meshheading:19564449-Administration, Oral,
pubmed-meshheading:19564449-Adolescent,
pubmed-meshheading:19564449-Anti-Asthmatic Agents,
pubmed-meshheading:19564449-Antibodies, Anti-Idiotypic,
pubmed-meshheading:19564449-Antibodies, Monoclonal,
pubmed-meshheading:19564449-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19564449-Asthma,
pubmed-meshheading:19564449-Child,
pubmed-meshheading:19564449-Drug Therapy, Combination,
pubmed-meshheading:19564449-Female,
pubmed-meshheading:19564449-Forced Expiratory Volume,
pubmed-meshheading:19564449-Glucocorticoids,
pubmed-meshheading:19564449-Humans,
pubmed-meshheading:19564449-Hypersensitivity,
pubmed-meshheading:19564449-Male,
pubmed-meshheading:19564449-Office Visits,
pubmed-meshheading:19564449-Severity of Illness Index,
pubmed-meshheading:19564449-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
|
|
pubmed:affiliation |
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936-1080, USA. marc.massanari@novartis.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
